| Literature DB >> 24250229 |
Qingfu Zhang1, Liying Yin, Bo Li, Rui Meng, Runa Dao, Suxiang Hu, Xueshan Qiu.
Abstract
Adenocarcinoma is the most common type of malignant pulmonary tumor, but osseous metaplasia of this tumor is extremely rare. To date, only 21 cases have been reported in the literature worldwide. Here, we report a case of primary pulmonary adenocarcinoma with benign osseous stromal metaplasia in a 60-year-old woman and discuss the pathogenesis of intratumoral ossification and review the relevant literature. We found that pulmonary adenocarcinoma with osseous metaplasia may be more likely to occur in early tumor stages.Entities:
Keywords: immunohistochemistry; osseous metaplasia; pulmonary adenocarcinoma
Year: 2013 PMID: 24250229 PMCID: PMC3829678 DOI: 10.2147/OTT.S48195
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Computed tomography scan showed an irregular abnormal soft tissue mass located in the left upper lobe.
Figure 2(A) Tumor showing the moderately differentiated adenocarcinoma growing with a born formation. Hematoxylin and eosin staining, original magnification ×50. Scale bar 1 mm. (B) Mature bony trabeculae in the abundant fibroblastic stroma were surrounded by osteoblasts. Hematoxylin and eosin staining, original magnification ×100. Scale bar 600 μm.
Figure 3(A) On immunohistochemical analysis, tumor cells were positive for cytokeratin 7. (B) TTF-1 immunohistochemistry shows strong nucleus staining in the tumor cells, original magnification ×100. Scale bar 400 μm.
Abbreviation: TTF-1, thyroid transcription factor-1.
Summary of previously reported cases of heterotopic mesenteric ossification
| Reference | Sex/age | Size (cm) | Histological type | P stage | TNM | Operation | CT/RT | Follow-up |
|---|---|---|---|---|---|---|---|---|
| McLendon et al | M/62 | 3 | Adeno/mod | IIIA | T1N2M0 | Lob | NA | NA |
| Yoshida et al | M/49 | 3.5 | Adeno/mod | IIB | T2N1M0 | Lob | NA | Recur, 60 months |
| Miyata et al | F/62 | 3.3 | Adeno/well | IB | T2N0M0 | Lob | NA | NA |
| Fukuse et al | M/61 | 4.5 | Adeno/mod | IB | T2N0M0 | Lob | NA | NA |
| Hayakawa et al | M/53 | NA | Adeno/mod | IV | T?N2M1 | Autopsy | RT | Dead, 33 months |
| Tsuchiya et al | F/70 | NA | NA | IA | T1N0M0 | Lob | NA | NA |
| Hara et al | F/70 | 3.2 | Adeno/mod | IIIB | T4N2M0 | Lob | NA | Alive, 6 months |
| Hosoda et al | M/66 | 3 | Adeno/mod | IA | T1N0M0 | Lob | NA | NA |
| Usami et al | M/46 | 4.5 | Adeno/poor | IB | T2N0M0 | Lob | NA | Alive, 14 months |
| Ueshima et al | F/73 | NA | NA | NA | NA | Lob | NA | NA |
| Kato et al | M/76 | 1.5 | NA | IA | T1N0M0 | Lob | NA | NA |
| Kim et al | F/65 | 3.2 | Adeno/mod | IB | T2N0M0 | Lob | NA | Alive, 52 months |
| Kim et al | M/70 | 4 | Adeno/mod | IIB | T2N1M0 | Bilob | CT | Alive, 49 months |
| Kim et al | M/63 | 3.7 | Adeno/mod | IB | T2N0M0 | Lob | CT | Alive, 43 months |
| Kim et al | F/65 | 6 | Adeno/mod | IB | T2N0M0 | Lob | NA | Alive, 27 months |
| Kim et al | M/57 | 4.5 | Adeno/mod | IB | T2N0M0 | Lob | NA | Alive, 14 months |
| Kim et al | F/66 | 2 | Adeno/poor | IIA | T1N1M0 | Lob | CT | Alive, 13 months |
| Kim et al | F/57 | 7 | Adeno/mod | IIIA | T2N2M0 | Lob | CT | Alive, 12 months |
| Kim et al | F/57 | 2.5 | Adeno/mod | IA | T1N0M0 | Lob | NA | Alive, 10 months |
| Kim et al | M/59 | 2.5 | Adeno/mod | IIIB | T4N0M0 | Lob | CT | Alive, 4 months |
| Kim et al | F/64 | 2.8 | Adeno/mod | IB | T2N0M0 | Lob | NA | Alive, 4 months |
| Present case | F/60 | 1.7 | Adeno/mod | IA | T1N0M0 | Lob | NA | Alive, 26 months |
Abbreviations: Adeno, adenocarcinoma; mod, moderately differentiated; well, well differentiated; NA, not available; Bilob, bilobectomy of right middle and lower lobe; Lob, lobectomy; CT, chemotherapy; Recur, recurrence; RT, radiation therapy.